AR013454A1 - Metodo para el tratamiento de las enfermedades pulmonares con 5'-difosfato de uridina y analogos del mismo, composiciones formuladas con dichos compuestosy los compuestos mencionados. - Google Patents
Metodo para el tratamiento de las enfermedades pulmonares con 5'-difosfato de uridina y analogos del mismo, composiciones formuladas con dichos compuestosy los compuestos mencionados.Info
- Publication number
- AR013454A1 AR013454A1 ARP980104305A ARP980104305A AR013454A1 AR 013454 A1 AR013454 A1 AR 013454A1 AR P980104305 A ARP980104305 A AR P980104305A AR P980104305 A ARP980104305 A AR P980104305A AR 013454 A1 AR013454 A1 AR 013454A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- treatment
- diphosphate
- formula
- uridine
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000019693 Lung disease Diseases 0.000 title abstract 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
- 229940045145 uridine Drugs 0.000 title abstract 2
- 239000001177 diphosphate Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005251 aryl acyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Se trata de un método para hidratar secreciones mucosas pulmonares, administrando compuestos de 5-difosfato de uridina de formula I en la cual X1y X2 son cada una, independientemente, O- o S-, X3 y X4 son cada una, independientemente, -H u -OH, con la condicion de que X3 y X4 no seansimultáneamente -H; R1 se selecciona del grupo que consiste en O, imido, metileno y dihalometileno (por ejemplo, diclorometileno, difluometileno); R2 seselecciona del grupo que consiste en H,halo, alquilo, alquilo sustituido, alcoxilo, nitro y azido; R3 se selecciona del grupo que consiste en H, alquilo,acilo (incluyendo arilacilo) y arilalquilo; y R4 tiene los valores indicados en la descripcion. Dicho método para el tratamiento de los desordenes pulmonares,tales como la fibrosis cística, la neumonía asociada con los ventiladores, la bronquitis cronica, el desorden pulmonar obstructivo cronico y la discinesiaciliar primaria. También se describen las composiciones farmacéuticas que contienen a los compuestos de la formula I y los nuevos compuestos de laformula I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5706497P | 1997-08-29 | 1997-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013454A1 true AR013454A1 (es) | 2000-12-27 |
Family
ID=22008285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104305A AR013454A1 (es) | 1997-08-29 | 1998-08-28 | Metodo para el tratamiento de las enfermedades pulmonares con 5'-difosfato de uridina y analogos del mismo, composiciones formuladas con dichos compuestosy los compuestos mencionados. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US6143279A (es) |
| EP (1) | EP1011688B1 (es) |
| JP (1) | JP2001513568A (es) |
| KR (1) | KR20010023359A (es) |
| CN (1) | CN1268056A (es) |
| AR (1) | AR013454A1 (es) |
| AT (1) | ATE288273T1 (es) |
| AU (1) | AU9124998A (es) |
| BR (1) | BR9811612A (es) |
| CA (1) | CA2300146A1 (es) |
| DE (1) | DE69828892D1 (es) |
| ID (1) | ID29198A (es) |
| WO (1) | WO1999009998A1 (es) |
| ZA (1) | ZA987847B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| US6872710B2 (en) * | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| DK1012154T3 (da) | 1997-07-25 | 2004-07-26 | Inspire Pharmaceuticals Inc | Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf |
| ATE288273T1 (de) * | 1997-08-29 | 2005-02-15 | Univ North Carolina | Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen |
| WO2000039145A1 (en) * | 1998-12-23 | 2000-07-06 | The University Of North Carolina At Chapel Hill | Targeted gene transfer using g protein coupled receptors |
| AU3612600A (en) * | 1999-02-26 | 2000-09-14 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
| EP1190249A2 (en) * | 1999-06-08 | 2002-03-27 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
| US7241447B1 (en) * | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| EP1282707A2 (en) * | 2000-05-11 | 2003-02-12 | Bayer Aktiengesellschaft | Regulation of human p2y-like g protein-coupled receptor |
| US6864243B1 (en) | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7109181B2 (en) | 2001-06-25 | 2006-09-19 | Inspire Pharmaceuticals, Inc. | Joint lubrication with P2Y purinergic receptor agonists |
| EP1427738A1 (fr) * | 2001-09-14 | 2004-06-16 | Université de Liège | Preparation de composes organiques triphosphoryles eventuellement marques au phosphore 32 ou au phosphore 33 |
| WO2003028712A2 (en) * | 2001-09-28 | 2003-04-10 | Universite Libre De Bruxelles | Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases |
| US7256183B2 (en) * | 2001-11-06 | 2007-08-14 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| EP1485395A4 (en) * | 2002-02-28 | 2011-04-13 | Biota Scient Management | NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF |
| WO2004037167A2 (en) * | 2002-10-18 | 2004-05-06 | Molichem Medicines, Inc. | Methods of treating dry eye disease with lantibiotics |
| US7749491B2 (en) * | 2003-03-31 | 2010-07-06 | University Of Iowa Research Foundation | Compounds and methods to enhance rAAV transduction |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| EP1750740A4 (en) | 2004-05-06 | 2009-06-10 | Molichem Medicines Inc | TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS |
| WO2005115432A2 (en) * | 2004-05-06 | 2005-12-08 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
| GB0417886D0 (en) * | 2004-08-11 | 2004-09-15 | Univ Cardiff | Method and means for enhanced pulmonary delivery |
| US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
| US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| HUP0600042A3 (en) * | 2006-01-19 | 2012-12-28 | Debreceni Egyetem | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides |
| WO2008113072A2 (en) | 2007-03-15 | 2008-09-18 | Board Of Regents, The University Of Texas System | Gpcr enhanced neuroprotection to treat brain injury |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| ES2640485T3 (es) | 2011-08-12 | 2017-11-03 | Universitätsklinikum Freiburg | Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica |
| CN107353316B (zh) | 2011-09-30 | 2020-08-18 | 塔夫斯大学 | 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法 |
| US9833207B2 (en) | 2012-08-08 | 2017-12-05 | William Harrison Zurn | Analysis and clearing module, system and method |
| CA2885369A1 (en) | 2012-09-28 | 2014-04-03 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
| EP2931712B8 (en) | 2012-12-17 | 2018-05-23 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| US9962533B2 (en) | 2013-02-14 | 2018-05-08 | William Harrison Zurn | Module for treatment of medical conditions; system for making module and methods of making module |
| AR095442A1 (es) | 2013-03-13 | 2015-10-14 | Univ Tufts | Derivados de nucleósido de uridina, composiciones y métodos de uso |
| CA2904180C (en) * | 2013-03-13 | 2022-05-10 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| WO2015021358A2 (en) | 2013-08-09 | 2015-02-12 | Dominique Charmot | Compounds and methods for inhibiting phosphate transport |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
| MX2018010842A (es) | 2016-03-07 | 2019-07-04 | Univ Iowa Res Found | Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico. |
| WO2017205739A1 (en) | 2016-05-26 | 2017-11-30 | University Of Iowa Research Foundation | cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1 |
| US11142775B2 (en) | 2017-01-13 | 2021-10-12 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
| KR102790402B1 (ko) * | 2019-12-18 | 2025-04-03 | 주식회사 종근당 | 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE639386A (es) * | 1962-10-30 | |||
| DE2122529A1 (de) * | 1971-05-06 | 1972-12-14 | Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen | Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung |
| JPS5415073B2 (es) * | 1972-09-14 | 1979-06-12 | ||
| US4058601A (en) * | 1974-07-11 | 1977-11-15 | Chugai Seiyaku Kabushiki Kaisha | Method for treating alcoholism |
| US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| DE3709851A1 (de) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
| GB9027968D0 (en) * | 1990-12-22 | 1991-02-13 | Fisons Plc | Method of treatment |
| EP0517573A1 (fr) * | 1991-06-05 | 1992-12-09 | Synthelabo | Compositions pharmaceutiques pour le traitement des affections des voies respiratoires |
| US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
| US5656256A (en) * | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
| US5635160A (en) * | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| ES2264197T3 (es) * | 1997-02-06 | 2006-12-16 | Inspire Pharmaceuticals, Inc. | Dinucleotidos y sus usos. |
| SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
| ATE288273T1 (de) * | 1997-08-29 | 2005-02-15 | Univ North Carolina | Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen |
-
1998
- 1998-08-28 AT AT98943457T patent/ATE288273T1/de not_active IP Right Cessation
- 1998-08-28 CA CA002300146A patent/CA2300146A1/en not_active Abandoned
- 1998-08-28 EP EP98943457A patent/EP1011688B1/en not_active Expired - Lifetime
- 1998-08-28 AU AU91249/98A patent/AU9124998A/en not_active Abandoned
- 1998-08-28 AR ARP980104305A patent/AR013454A1/es not_active Application Discontinuation
- 1998-08-28 CN CN98808470A patent/CN1268056A/zh active Pending
- 1998-08-28 WO PCT/US1998/017894 patent/WO1999009998A1/en not_active Ceased
- 1998-08-28 US US09/143,297 patent/US6143279A/en not_active Expired - Lifetime
- 1998-08-28 ID IDW991714A patent/ID29198A/id unknown
- 1998-08-28 ZA ZA987847A patent/ZA987847B/xx unknown
- 1998-08-28 JP JP2000507388A patent/JP2001513568A/ja active Pending
- 1998-08-28 BR BR9811612-6A patent/BR9811612A/pt not_active IP Right Cessation
- 1998-08-28 DE DE69828892T patent/DE69828892D1/de not_active Expired - Lifetime
- 1998-08-28 KR KR1020007001997A patent/KR20010023359A/ko not_active Withdrawn
-
1999
- 1999-07-13 US US09/352,390 patent/US6022527A/en not_active Expired - Lifetime
-
2000
- 2000-08-24 US US09/645,161 patent/US6451288B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU9124998A (en) | 1999-03-16 |
| DE69828892D1 (de) | 2005-03-10 |
| ZA987847B (en) | 1999-06-28 |
| CN1268056A (zh) | 2000-09-27 |
| WO1999009998A1 (en) | 1999-03-04 |
| ID29198A (id) | 2001-08-09 |
| BR9811612A (pt) | 2000-08-08 |
| US6451288B1 (en) | 2002-09-17 |
| US6022527A (en) | 2000-02-08 |
| EP1011688A1 (en) | 2000-06-28 |
| KR20010023359A (ko) | 2001-03-26 |
| JP2001513568A (ja) | 2001-09-04 |
| EP1011688B1 (en) | 2005-02-02 |
| ATE288273T1 (de) | 2005-02-15 |
| US6143279A (en) | 2000-11-07 |
| CA2300146A1 (en) | 1999-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013454A1 (es) | Metodo para el tratamiento de las enfermedades pulmonares con 5'-difosfato de uridina y analogos del mismo, composiciones formuladas con dichos compuestosy los compuestos mencionados. | |
| NO993776D0 (no) | Gitte dinukleotider og deres anvendelse som modulatorer av mukociliaer renselse og ciliaer stötfrekvens | |
| UY33494A (es) | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen | |
| CY1105301T1 (el) | Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις | |
| PE131099A1 (es) | Compuestos terapeuticamente activos basados en el reemplazo bioisostero del catecol por el indazol en inhibidores de pde4 | |
| AR042578A1 (es) | Inhibidores de la sintesis de mucina | |
| HRP20201378T1 (hr) | Pripravci i postupci za modulaciju ekspresije apolipoproteina (a) | |
| NZ504986A (en) | Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents | |
| BR9712073A (pt) | Processo para produção de compostos de ecteinascidina | |
| PT1063885E (pt) | Composicoes de xilitol para tratar patologias respiratorias superiores | |
| CO6310968A2 (es) | Derivados de 3,5-diamino sustituido-n-tetrahidropirimidin/imidazolin/diazepam-2-ilidenpirazin-2-carboxamida, utiles como bloqueadores de la actividad del canal de sodio epitelial (enac) | |
| DK1353911T3 (da) | Antivirale midler | |
| AU2272497A (en) | Method of treating otitis media with uridine triphosphates and related compounds | |
| MEP9509A (en) | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof | |
| SV1998000029A (es) | Compuestos de pirazina ref. pg3186 | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| BR9809022A (pt) | Composições antiinflamatórias nasais tópicas | |
| ATE260928T1 (de) | Ketolidantibiotika | |
| DK0984019T3 (da) | C11-carbamater fra antibakterielle macrolider | |
| ATE386548T1 (de) | Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren | |
| TR200102501T2 (tr) | Antiviral nükleozid analoglar. | |
| AR030332A1 (es) | Compuestos | |
| BRPI0204489B8 (pt) | "derivado de rodamina, composição farmacêutica, intermediário, e, processo para a síntese de novos derivados rodamina". | |
| PA8429501A1 (es) | Derivados de acido 3-aributirico sustituido como inhibidores de la metaloproteasa de matriz | |
| ES2157644T3 (es) | Nuevos derivados aminados del 6,7,8,9-tetrahidro-ciclopenta-(a)-naftaleno y del 2,3-dihidro-ciclopenta-(e)-indeno, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |